Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies
Cancer Drug Resistance · 28.11.2025
DOI: 10.20517/cdr.2025.148 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Drug Resistance, online erschienen am 28.11.2025. Verfasst von Yue Hao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, Jiangsu, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) have emerged as a transformative class in oncology, integrating the target specificity of monoclonal antibodies with the potent cytotoxicity of small-molecule payloads. By harnessing tumor-specific antigen recognition, ADCs enable the selective delivery of chemotherapeutic agents, thereby enhancing therapeutic efficacy while reducing systemic toxicity. Their clinical success across both hematologic malignancies and solid tumors underscores their potential to redefine targeted cancer therapy. However, the clinical durability of ADCs is increasingly undermined by the emergence of diverse resistance mechanisms that diminish their antitumor activity. These mechanisms encompass the entire drug delivery cascade - from reduced or heterogeneous antigen expression and impaired internalization to defective lysosomal trafficking, enhanced drug efflux, and payload detoxification. In addition, adaptive reprogramming of oncogenic signaling pathways and tumor microenvironmental factors can further attenuate ADC cytotoxicity and promote tumor persistence. A comprehensive understanding of the molecular and cellular bases of ADC resistance is essential for sustaining their therapeutic impact. Advances in linker chemistry, innovative payload design, and the development of bispecific or immune-modulating ADCs offer promising strategies to overcome these challenges. Concurrently, the integration of biomarker-driven patient selection and rational combination regimens is poised to enhance treatment precision and delay resistance. Continued mechanistic and translational research will be pivotal to fully realizing the potential of next-generation ADCs in precision oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, Jiangsu, China.
- Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang, China.
Zitieren
APA
Hao, Y., & Song, Z. (2025). Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2025.148
Vancouver
Hao Y, Song Z. Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies. Cancer Drug Resistance. 2025. doi:10.20517/cdr.2025.148
BibTeX
@article{Hao2025,
author = {Hao, Yue and Song, Zhengbo},
title = {Mechanisms of resistance to antibody-drug conjugates in cancer therapy: molecular basis and therapeutic strategies},
journal = {Cancer Drug Resistance},
year = {2025},
doi = {10.20517/cdr.2025.148}
}
EUVIMED